Weleader Biomedical Co (ROCO:7713) Accounts Payable: NT$199 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7713 Weleader Biomedical Co Ltd ROCO:7713
42 GF Score
Price NT$70.00
! 5 Warning Signs
View Full Analysis

What is Weleader Biomedical Co Accounts Payable?

Weleader Biomedical Co ROCO:7713 42 Accounts Payable is NT$199 Mil as of Mar. 2026. GuruFocus rates ROCO:7713 with a GF Score™ of 42/100. The stock has 5 warning signs investors should review.

Weleader Biomedical Co's Accounts Payable for the quarter that ended in Mar. 2026 was NT$199 Mil.

Weleader Biomedical Co's quarterly Accounts Payable declined from Sep. 2025 (NT$216 Mil) to Dec. 2025 (NT$204 Mil) and declined from Dec. 2025 (NT$204 Mil) to Mar. 2026 (NT$199 Mil).

Weleader Biomedical Co's annual Accounts Payable increased from Dec. 2023 (NT$143 Mil) to Dec. 2024 (NT$184 Mil) and increased from Dec. 2024 (NT$184 Mil) to Dec. 2025 (NT$204 Mil).

Weleader Biomedical Co Accounts Payable Related Terms

Weleader Biomedical Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Weleader Biomedical Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Weleader Biomedical Co Accounts Payable Chart

Weleader Biomedical Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 157.74 155.28 143.19 183.54 203.93

Weleader Biomedical Co Quarterly Data
Dec20 Dec21 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 203.28 217.59 215.65 203.93 199.10
ROCO:7713
42GF Score
Weleader Biomedical Co Ltd ROCO:7713
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Weleader Biomedical Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of NT$199 Mil mean?
Weleader Biomedical Co (ROCO:7713) has a Accounts Payable of NT$199 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Weleader Biomedical Co and its competitors.
Is Weleader Biomedical Co's Accounts Payable too high?
Weleader Biomedical Co's current Accounts Payable is NT$199 Mil. Overall, Weleader Biomedical Co has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Weleader Biomedical Co's Accounts Payable compare to ABT and SYK?
Weleader Biomedical Co's Accounts Payable of NT$199 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Medical Devices & Instruments company?
A good Accounts Payable depends on the Medical Devices & Instruments industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Weleader Biomedical Co and its competitors. Weleader Biomedical Co's current Accounts Payable is NT$199 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weleader Biomedical Co stock overvalued right now?
Weleader Biomedical Co (ROCO:7713) has a current Accounts Payable of NT$199 Mil. The current Accounts Payable is NT$199 Mil. Weleader Biomedical Co's overall GF Score™ is 42/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Weleader Biomedical Co (ROCO:7713), the current Accounts Payable is NT$199 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weleader Biomedical Co Business Description

Address No. 80, Minzu 1st Road, 19th Floor - 1 & 2, Sanmin District, Kaohsiung, TWN
Weleader Biomedical Co Ltd is mainly engages in the sales of medical testing reagents and medical devices; and the leasing of testing instruments. The reportable segments of the Group are: The Company, which includes sale of testing reagents, and provision of testing instruments and services; and Health Leader, which includes sale of dietary supplements and testing reagents, and provision of information and professional services. It derives majority revenue from the Company segment. Geographically, the company operates and generates revenue from Taiwan.
42GF Score

Get the complete analysis for ROCO:7713

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$70.00
Price